ArticleCancer & metabolism2026
The FGL1-LAG-3 axis attenuates melanoma-induced cachexia in mice.
Article in Cancer & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cachexia is a debilitating condition characterized by the wasting of adipose and skeletal muscle tissues, resulting in significant weight loss and frailty. It is responsible for 20% of cancer-related mortalities. Despite its clinical significance, the precise mechanisms underlying cachexia remain inadequately understood. Our gene expression analysis of white adipose tissues has identified an upregulation of fibrinogen-like protein 1 (FGL1) in B16F10 tumor-bearing mice. In this study, we demonstrate that the intraperitoneal administration of FGL1 protein mitigates tumor-induced wasting of adipose and muscle tissues in mice. Correspondingly, FGL1 treatment reverses the expression patterns of genes associated with lipid metabolism and muscle degradation. Mechanistically, our research establishes that lymphocyte activation gene-3 (LAG-3) serves as a critical mediator of FGL1’s anti-cachexia effects. These findings suggest that FGL1 acts as a crucial intermediary between tumor presence and the processes of adipose catabolism and muscle wasting, thereby identifying the FGL1-LAG-3 signaling axis as a promising therapeutic target for cancer cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.